SCHEMBL4479510

SCHEMBL4479510

OC(c1ccccc1)C(c1ccccc1)N1CCN(Cc2ccccc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.60
ATM Q13315 2/20 0.60
SIGMAR1 Q99720 2/20 0.56
SCN5A Q14524 1/20 0.52
SCN9A Q15858 1/20 0.52
MAOB P27338 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
IGF1R P08069 1/20 0.50
HTT P42858 1/20 0.49
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49
MC4R P32245 1/20 0.49
HDAC4 P56524 1/20 0.48
KCNH2 Q12809 1/20 0.48
HDAC1 Q13547 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13509120 1.00 KDM4E (0.60) KDM4EATMSIGMAR1SCN5ASCN9A
SCHEMBL11815091 0.87 SIGMAR1 (0.63) KDM4ESIGMAR1HTTLMNA
Hydrochloric Acid SCHEMBL11822882 0.86 SIGMAR1 (0.62) KDM4ESIGMAR1HTTLMNA
SCHEMBL4473753 0.83 KDM4E (0.59) KDM4EATMSIGMAR1MEN1KMT2A
SCHEMBL20804561 0.83 MEN1 (0.59) KDM4EATMSIGMAR1SCN5ASCN9A
SCHEMBL25732897 0.82 KDM4E (0.66) KDM4EATMSIGMAR1SCN5ASCN9A
SCHEMBL11820910 0.82 SIGMAR1 (0.56) KDM4ESIGMAR1MEN1KMT2AHTT
SCHEMBL13509152 0.81 SIGMAR1 (0.56) KDM4EATMSIGMAR1SCN5ASCN9A
Hydrochloric Acid SCHEMBL11820828 0.81 SIGMAR1 (0.55) KDM4ESIGMAR1MEN1KMT2AHTT
SCHEMBL16835752 0.80 SIGMAR1 (0.69) KDM4EATMSIGMAR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576086-B2 N1-benzyl-N4-(phenylpropane-2-yl-3-ol)piperazine; triple action on hydroxytryptamine (5-HT), noradrenalin (NA)and dopamine(DA); on brain synapses; cytochrome P-450 monooxygenase enzyme system antagonists; enzyme inhibitors; side effect reduction SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2009-08-18 US claimed
US-20050267121-A1 Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2005-12-01 US claimed
US-7576086-B2 N1-benzyl-N4-(phenylpropane-2-yl-3-ol)piperazine; triple action on hydroxytryptamine (5-HT), noradrenalin (NA)and dopamine(DA); on brain synapses; cytochrome P-450 monooxygenase enzyme system antagonists; enzyme inhibitors; side effect reduction SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2009-08-18 US disclosed
US-20050267121-A1 Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267121-A1 Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant AANAT, GAP43, TPH2 KDM4E 2865/4885ATM 3870/4885SIGMAR1 805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.